Want to see SE:BIOSGN full AI Analyst Report?
BIOSGN Stock Chart & Stats
kr42.60
<kr0.01(1.20%)
At close: 4:00 PM EST
kr42.60
<kr0.01(1.20%)
Day’s Range― - ―
52-Week Rangekr0.47 - kr7.30
Previous CloseN/A
Volume13.64K
Average Volume (3M)529.58K
Market Cap
kr45.20M
Enterprise Valuekr77.44
Total Cash (Recent Filing)kr3.23M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.61
Shares Outstanding82,188,120
10 Day Avg. Volume820,545
30 Day Avg. Volume529,584
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)72.03
Price to Sales (P/S)0.00
P/FCF Ratio-23.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.1
Revenue Forecast (FY)kr1.40M
Bulls Say, Bears Say
Bulls Say
Focused Antifungal PipelineThe company has a clearly defined therapeutic focus and a lead asset addressing invasive fungal infections. Concentrating resources on BSG005 may help align research priorities, clinical development, and potential partnering efforts around one identifiable platform opportunity.
No Financial DebtAn absence of financial debt reduces solvency and interest-burden risk while the company remains in research and development. This gives management more flexibility than a similarly loss-making biotech with lenders, although external funding is still needed to sustain operations.
Year-over-year Loss ImprovementThe reduction in reported net loss from 2025 to the latest trailing period indicates some improvement in operating performance, even though losses remain substantial. If maintained, lower losses could extend available resources and reduce the pace of funding needs over subsequent periods.
Bears Say
No Visible Revenue BaseThe absence of a visible revenue base means the company has not yet demonstrated commercial monetization in its reported financials. This leaves future operating economics dependent on successful development, regulatory progress, and eventual product or partnership income.
Heavy Recurring Cash BurnPersistently negative operating and free cash flow shows that current activities consume substantial cash rather than funding themselves. Continued burn increases dependence on external capital and can constrain research priorities, especially if financing conditions become less supportive.
Severely Compressed EquityThe sharp decline in equity indicates substantial cumulative burn and/or dilution effects, leaving a much thinner capital base. A smaller equity cushion reduces financial resilience and increases the importance of securing additional funding to maintain development activities.
Biosergen AB News
BIOSGN FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was kr0.47 and its highest was kr7.30 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is kr45.20M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Nov 18, 2026 which is in 61 days.
How were Biosergen AB’s earnings last quarter?
Biosergen AB released its earnings results on Feb 10, 2026. The company reported -kr0.581 earnings per share for the quarter.
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 82,188,120 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Biosergen AB reported an EPS of -kr0.581 in its last earnings report. Following the earnings report the stock price went up 6.015%.
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in SE:BIOSGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosergen AB
Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.
Technical Analysis
BioInvent International AB
―
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Immunicum AB
―
Cantargia AB
―